AP
VIR icon

Aspect Partners’s Vir Biotechnology VIR Stock Holding History

Aspect Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-646
Closed -$3.9K – 742
2025
Q4 		$3.9K Buy
646
+65
+11% +$387 ﹤0.01% 420
2025
Q3 		$3.32K Buy
+581
New +$2.97K ﹤0.01% 471

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Aspect Partners's VIR Position: Q1 2026 in Review

Aspect Partners sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 646 shares — an estimated $3.9K sold.

Aspect Partners first reported a position in VIR in Q3 2025 and held it in 2 quarters. The position peaked at $3.9K in Q4 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Aspect Partners reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Aspect Partners sold 646 Vir Biotechnology shares in Q1 2026, an estimated $3.9K.
  • Aspect Partners first reported a position in Vir Biotechnology in Q3 2025 and held it in 2 quarters.
  • Aspect Partners's Vir Biotechnology position peaked at $3.9K in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Aspect Partners's 13F filing for Q1 2026, filed 2 Apr 2026.